Insider Selling: Insulet Co. (PODD) EVP Sells 602 Shares of Stock

Insulet Co. (NASDAQ:PODD) EVP Aiman Abdel-Malek sold 602 shares of the company’s stock in a transaction that occurred on Monday, October 15th. The stock was sold at an average price of $88.58, for a total transaction of $53,325.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Aiman Abdel-Malek also recently made the following trade(s):

  • On Friday, September 14th, Aiman Abdel-Malek sold 602 shares of Insulet stock. The stock was sold at an average price of $107.99, for a total transaction of $65,009.98.
  • On Tuesday, August 14th, Aiman Abdel-Malek sold 602 shares of Insulet stock. The stock was sold at an average price of $86.60, for a total transaction of $52,133.20.

Shares of NASDAQ PODD opened at $90.10 on Friday. Insulet Co. has a one year low of $56.62 and a one year high of $108.90. The company has a debt-to-equity ratio of 3.22, a current ratio of 5.54 and a quick ratio of 5.01.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Thursday, August 2nd. The medical instruments supplier reported ($0.03) EPS for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.10. Insulet had a negative net margin of 3.47% and a negative return on equity of 11.91%. The business had revenue of $124.26 million for the quarter, compared to analysts’ expectations of $132.89 million. During the same period last year, the business earned ($0.13) earnings per share. The business’s quarterly revenue was up 13.2% on a year-over-year basis. Equities research analysts forecast that Insulet Co. will post -0.09 earnings per share for the current year.

PODD has been the topic of several research analyst reports. Leerink Swann restated an “outperform” rating and issued a $130.00 price objective on shares of Insulet in a research report on Tuesday, September 11th. Zacks Investment Research upgraded shares of Insulet from a “hold” rating to a “buy” rating and set a $119.00 price objective on the stock in a research report on Monday, October 1st. BidaskClub upgraded shares of Insulet from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, September 11th. Morgan Stanley increased their price target on shares of Insulet from $96.00 to $105.00 and gave the company an “equal weight” rating in a research report on Thursday, October 11th. Finally, Oppenheimer set a $96.00 price target on shares of Insulet and gave the company a “hold” rating in a research report on Friday, August 3rd. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the company’s stock. Insulet currently has an average rating of “Buy” and an average target price of $99.13.

A number of hedge funds and other institutional investors have recently modified their holdings of PODD. New York State Common Retirement Fund boosted its stake in shares of Insulet by 5.7% during the first quarter. New York State Common Retirement Fund now owns 84,496 shares of the medical instruments supplier’s stock valued at $7,324,000 after purchasing an additional 4,524 shares during the period. Dimensional Fund Advisors LP boosted its stake in shares of Insulet by 17.7% during the first quarter. Dimensional Fund Advisors LP now owns 103,768 shares of the medical instruments supplier’s stock valued at $8,995,000 after purchasing an additional 15,610 shares during the period. Principal Financial Group Inc. boosted its stake in shares of Insulet by 5.8% during the first quarter. Principal Financial Group Inc. now owns 37,618 shares of the medical instruments supplier’s stock valued at $3,261,000 after purchasing an additional 2,076 shares during the period. Allianz Asset Management GmbH boosted its stake in shares of Insulet by 24.4% during the first quarter. Allianz Asset Management GmbH now owns 20,749 shares of the medical instruments supplier’s stock valued at $1,798,000 after purchasing an additional 4,074 shares during the period. Finally, UBS Group AG boosted its stake in shares of Insulet by 194.9% during the first quarter. UBS Group AG now owns 10,687 shares of the medical instruments supplier’s stock valued at $926,000 after purchasing an additional 7,063 shares during the period.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device.

Featured Story: Understanding Price to Earnings Ratio (PE)

Insider Buying and Selling by Quarter for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply